Has Taofeek Owonikoko received payments from drug or device companies?

Yes. Drug and device makers reported $9,732,665 in general payments to Taofeek Owonikoko across 624 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Taofeek Owonikoko did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Taofeek Owonikoko come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Taofeek Owonikoko

Hematology & Oncology · Pittsburgh, PANPI 1578770871

Payments from drug & device makers

$9,732,665in general payments, 2019–2025

Across 624 payments — averaging $15,597 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$2.8M
Y-mabs Therapeutics, Inc.$1.7M
Amgen$1.1M
Novartis$831K
AstraZeneca$783K
Merck$500K
plus $2M from 36 others

$17,518in research payments, 2019–2025

Across 24 payments — averaging $729.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$10K
Amgen$2K
EMD Serono, Inc.$2K
Pfizer$1K
GSK$1K
Novartis$1K
plus $92 from 1 others

What the payments were for

Consulting fees$264,05876%
Speaking & faculty fees$13,0684%
Travel & lodging$62,63318%
Food & beverage$5,4712%
Education$1,1500%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	21	$2,774,218
Y-mabs Therapeutics, Inc.	61	$1,745,751
Amgen	46	$1,075,008
Novartis	38	$831,018
AstraZeneca	63	$783,205
Merck	61	$500,362
Puma Biotechnology, Inc.	20	$432,866
Eli Lilly	9	$334,961
Regeneron	23	$226,287
Boehringer Ingelheim	13	$193,375
GSK	32	$160,401
Eisai Inc.	20	$124,322
United Therapeutics Corporation	13	$102,904
E.r. Squibb & Sons, L.L.C.	20	$69,709
Daiichi Sankyo Inc.	24	$62,144
F. Hoffmann-la Roche AG	5	$55,217
Genentech, Inc.	6	$45,647
Astrazeneca UK Limited	18	$29,350
Boehringer Ingelheim International GmbH	18	$27,436
Ipsen Bioscience Inc.	11	$21,755
Gilead	6	$20,239
AbbVie	7	$18,839
Bayer	18	$15,830
Incyte Corporation	4	$15,485
Jazz Pharmaceuticals Inc.	5	$14,718
Boehringer Ingelheim Pharma GmbH & Co.kg	28	$10,910
Astrazeneca AB	10	$9,945
Ipsen Biopharmaceuticals, Inc	1	$6,200
Genentech USA, Inc.	6	$4,157
Janssen Scientific Affairs, LLC	5	$4,069
EMD Serono, Inc.	1	$3,000
Organon	1	$2,500
Merck Kgaa	1	$2,400
Janssen Global Services, LLC	1	$1,890
Exelixis Inc.	1	$1,650
Bristol Myers Squibb	1	$1,625
Catalyst Pharmaceuticals, Inc.	1	$1,500
Beigene, Ltd.	1	$1,322
Eagle Pharmaceuticals, Inc.	1	$149
Johnson & Johnson	1	$113
Comsort, Inc	1	$100
Genmab U.S., Inc.	1	$88

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

IMFINZI$47,841
LUMAKRAS$22,030
TAGRISSO$16,725
ZEPZELCA$14,678
Vitrakvi$9,253
LENVIMA$8,110
LIBTAYO$7,913
ILARIS$7,895
KEYTRUDA$7,271
IMDELLTRA (AMG 757)$6,860
ONIVYDE$6,200
TABRECTA$4,730
Tepotinib$3,000
Trodelvy$2,047
MK-7339$2,000
Cabometyx$1,650
TECENTRIQ$1,640
FIRDAPSE$1,500
PEMFEXY$149
DARZALEX$113

How this compares

$9,732,665 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.

See all hematology & oncology providers in Pennsylvania →

Other hematology & oncology in Pittsburgh

Diwakar DavarPittsburgh$21.6M
Jason LukePittsburgh$15M
Leonard ApplemanPittsburgh$12.8M
Jing Zhou HouPittsburgh$11.9M
Ahmad TarhiniPittsburgh$7.4M
Samuel JacobsPittsburgh$6.5M
Cyrus KhanPittsburgh$4.5M
Kathleen DorritiePittsburgh$3.2M
Salman FazalPittsburgh$2.9M
Mounzer AghaPittsburgh$2.6M

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →